On Thursday, TD Cowen adjusted its outlook on Johnson & Johnson (NYSE:JNJ) shares, lowering the price target to $185 from the previous $195 while maintaining a Buy rating on the stock. The revision follows Johnson & Johnson's recent quarterly financial results, which surpassed Wall Street's expectations.
Johnson & Johnson reported a second-quarter revenue of $22.45 billion and earnings per share (EPS) of $2.82. These figures beat the forecasts, which had projected revenues of $22.32 billion and EPS of $2.71. Despite the strong performance, the company has adjusted its earnings guidance for the year.
The healthcare giant has maintained its 2024 adjusted operational sales growth forecast in the range of 5.5-6.0%. However, it has revised its 2024 adjusted operational EPS guidance, lowering it to a range of $10.00-$10.10, down from the previously anticipated $10.60-$10.75.
The updated EPS guidance takes into account a $0.68 negative impact from recent mergers and acquisitions. Nevertheless, this is somewhat offset by a slight improvement in the performance outlook since April, which has contributed an additional $0.05.
Investors and market watchers will continue to monitor Johnson & Johnson's financial health and operational performance closely, especially in light of the revised earnings expectations and the ongoing strategic business activities.
In other recent news, healthcare giant Johnson & Johnson reported strong second-quarter results, with revenues reaching $22.4 billion and adjusted earnings per share at $2.82. The company has revised its 2024 sales forecast to between $89.2 billion and $89.6 billion, reflecting its robust performance.
However, it has also adjusted its earnings per share expectations downward due to the impact of mergers and acquisitions. Among these, Johnson & Johnson has acquired Yellow (OTC:YELLQ) Jersey for $1.25 billion and Shockwave for $13 billion.
RBC Capital has reiterated its Outperform rating on Johnson & Johnson's stock, citing a valuation currently below historical averages and potential upcoming catalysts. Despite some mixed forecasts for its divisions, the company expects a stronger second half of the year for its Medical Technology segment. However, the Innovative Medicine division might see a growth moderation due to a biosimilar competitor for its drug Stelara in the European market.
Investors have shown dynamic activities surrounding Johnson & Johnson. Kevin Hern has increased his holdings in the company through dividend reinvestment, while Richard Allen sold his stake. These recent developments underscore the ongoing interest in Johnson & Johnson as it navigates through the remainder of the year.
InvestingPro Insights
Following TD Cowen's recent adjustment of Johnson & Johnson's (NYSE:JNJ) price target, InvestingPro data shows a robust financial picture for the company. With a market capitalization of $373.88 billion and a P/E ratio that has improved to 19.4 from the last twelve months as of Q1 2024, Johnson & Johnson remains a heavyweight in the pharmaceutical sector. Notably, the company's revenue growth has been healthy, with a 10.57% increase over the last twelve months leading up to Q1 2024, reflecting its solid market performance.
InvestingPro Tips highlight Johnson & Johnson's commitment to shareholders, as evidenced by its impressive track record of raising dividends for 54 consecutive years, showcasing a reliable return on investment. Additionally, the company's stock is characterized by low price volatility, which may appeal to risk-averse investors. For those looking to delve deeper into the company's prospects, InvestingPro offers even more analysis, with a total of 12 tips available, providing a comprehensive view of Johnson & Johnson's financial health and market potential.
Investors considering Johnson & Johnson can use the coupon code PRONEWS24 to get up to 10% off a yearly Pro and a yearly or biyearly Pro+ subscription, unlocking further insights that could inform their investment decisions.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.